Search
Refine your search
89 results found
Carpmaels & Ransford LLP | United Kingdom, European Union | 8 Aug 2018
UKIPO helps to clarify the future UK-EU relationship on intellectual property
The UK Intellectual Property Office has published an update to its page “IP and BREXIT: The facts”. Although by no means a detailed legal proposal
Carpmaels & Ransford LLP | United Kingdom | 25 Apr 2018
Claiming costs and expenses in High Court litigation as licensee
While there are many good reasons for recording a patent licence and keeping an up-to-date register, a recent High Court ruling illustrates the
Carpmaels & Ransford LLP | United Kingdom, European Union | 18 Apr 2018
IP rights - what does the future hold after Brexit?
The European Commission recently published its draft withdrawal agreement setting out its proposals for the arrangements surrounding the United
Carpmaels & Ransford LLP | European Union | 21 Mar 2018
Clarification of disclaimer practice at the EPO
In its recent G 116 decision, the European Patent Office (EPO) Enlarged Board of Appeal clarified how disclaimers should be examined. While
Carpmaels & Ransford LLP | United Kingdom, European Union | 13 Dec 2017
Progress for the UPC Agreement
The UK parliament has moved closer to ratification of the Unified Patent Court (UPC) Agreement with parliament’s approval of the remaining UK
Carpmaels & Ransford LLP | United Kingdom, European Union | 7 Dec 2017
SPCs: clarity on claims with functional features?
The German Federal Patent Court has asked the CJEU how its “implicitly, but necessarily and specifically” test for assessing Article 3(a) of
Carpmaels & Ransford LLP | United Kingdom | 29 Nov 2017
Unregistered IP rights may have significant consequences for interested parties
Registered IP rights can be highly valuable assets, but their creation, development, exploitation and acquisition require significant time, effort and
Carpmaels & Ransford LLP | United Kingdom | 24 Nov 2017
Actavis v ICOS
ICOS’s patent EP 1173181 is directed to a dosage regimen of the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, which is marketed by Lilly under
Carpmaels & Ransford LLP | European Union, Germany | 22 Nov 2017
New referral regarding SPC availability for certain medical devices
A new question has been referred to the European Court of Justice by the German Federal Patent Court on the availability of supplementary protection
Carpmaels & Ransford LLP | United Kingdom, European Union | 16 Nov 2017
Reasons for recordal 1, 2, 3
Failure to register intellectual property rights (IPRs) can lead to significant consequences for the interested parties Registered IPRs can be highly
